You are here

  • Home
  • Archive
  • Volume 17, Issue 6
  • Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer

Article Text

Article menu

Download PDFPDF

ORIGINAL ARTICLE
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer
  1. H. Yoshitake*,
  2. M. Takahashi*,
  3. H. Ishikawa†,
  4. M. Nojima‡,
  5. H. Iwanari§,
  6. A. Watanabe‖,
  7. H. Aburatani‖,
  8. K. Yoshida‡,
  9. K. Ishi,
  10. K. Takamori*,
  11. H. Ogawa*,
  12. T. Hamakubo#,
  13. T. Kodama# and
  14. Y. Araki*
  1. * Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan;
  2. † Department of Public Health, Yamagata University School of Medicine, Yamagata, Japan;
  3. ‡ Department of Obstetric and Gynecology, Juntendo University Urayasu Hospital, Chiba, Japan;
  4. § Perseus Proteomics, Inc., Tokyo, Japan;
  5. ‖ Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan;
  6. Department of Clinical Pathology, Juntendo University Urayasu Hospital, Chiba, Japan; and
  7. # Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
  1. Address correspondence and reprint requests to: Yoshihiko Araki, MD, DMedSci, Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu-City, Chiba, Japan. Email: yaraki{at}med.juntendo.ac.jp

Abstract

Aldo-keto reductase family 1, member B10 (AKR1B10), an enzyme that converts retinals into retinols is known to detect in non–small cell lung carcinoma (squamous cell- and adeno-carcinomas), but is barely expressed in normal tissues. Since these types of carcinoma occur frequently in the uterus (like in the lung), AKR1B10 may also be overexpressed in two major types of uterine cancer, cervical cancer (CC), and endometrial cancer (EMC). The objective of this study is to investigate AKR1B10 expression in uterine cancer and to analyze its clinical significance. In samples from uterine cancer patients, AKR1B10 was detected in 6 out of 30 (20.0%) CC cases and 6 out of 38 (15.8%) EMC cases. Statistical analysis indicated that AKR1B10 expression was associated with tumor recurrence after surgery and keratinization of squamous cell carcinoma only in CC. Although retinol (a metabolic product by AKR1B10) was observed in the normal epithelium, the molecule was not observed in cancer cells of AKR1B10-positive CC samples suggesting that the recurrence in CC may not depend on the convert of retinals into retinols via AKR1B10, a potential indicator in the management of patients with CC

  • AKR1B10
  • cervical cancer
  • endometrial cancer
  • immunohistochemistry
  • retinal

https://doi.org/10.1111/j.1525-1438.2007.00932.x

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.